SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB

SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB

SERB Pharmaceuticals has entered into an agreement to acquire the European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma AB. This strategic acquisition aims to expand SERB's rare disease portfolio. The deal, announced May 19, 2026, carries an upfront payment of €110 million with an additional €5 million in potential milestones, positioning SERB to broaden access to the enzyme therapy across two key geographies.

Key Takeaways

• SERB Pharmaceuticals has acquired exclusive European and Middle East/North Africa commercialization rights to Idefirix® (imlifidase) from Hansa Biopharma AB for an upfront €110 million plus €5 million in potential milestone payments.
• The transaction, announced May 19, 2026, is expected to close by Q4 2025 and was advised on by Mayer Brown on structuring and execution.
• Idefirix® is an enzyme therapy targeting IgG antibodies, with regulatory implications spanning the EMA's existing assessment framework and the heterogeneous approval pathways across MENA markets.
• The acquisition significantly deepens SERB's rare disease footprint and signals continued consolidation in the transplant-enzyme therapeutic space.

What Happened and Why It Matters

SERB Pharmaceuticals announced on May 19, 2026 that it had entered into a definitive agreement with Hansa Biopharma AB to acquire the European and MENA rights to Idefirix® (imlifidase). The total deal consideration comprises an upfront cash payment of €110 million, with Hansa eligible for an additional €5 million upon the achievement of a specified European Medicines Agency-related milestone. The transaction was structured with legal counsel from Mayer Brown, which advised SERB on the take-private arrangement.

Imlifidase is a cysteine protease derived from Streptococcus pyogenes that cleaves IgG antibodies, and it is approved in the EU under the brand name Idefirix® for desensitization treatment in highly sensitized kidney transplant patients. For SERB, the acquisition plugs a direct commercial channel into a niche but high-need therapeutic area where the company already maintains infrastructure. Hansa, meanwhile, retains rights outside the acquired territories and will continue to develop the asset for additional transplant indications.

The deal is expected to close by the fourth quarter of 2025, subject to customary closing conditions. Once completed, SERB assumes all commercial, regulatory, and distribution responsibilities for Idefirix® across the European Union member states and the MENA region.

Strategic Rationale and Market Implications

SERB Pharmaceuticals has been methodically building its rare disease and specialty biologics portfolio through targeted acquisitions. Adding European and MENA rights to Idefirix® extends the company's geographic reach beyond its existing markets and diversifies revenue concentration. The enzyme therapy addresses a well-defined unmet need—desensitizing patients with high levels of donor-specific antibodies who would otherwise remain on transplant waiting lists indefinitely.

The competitive dynamics in transplant immunology remain concentrated, with few approved therapies offering rapid IgG depletion. SERB's acquisition signals confidence that imlifidase's clinical profile can support broader adoption, particularly in European transplant centers where the EMA has already granted marketing authorization. Across MENA, market access varies widely; some Gulf Cooperation Council states reference EMA approvals, while others require independent dossier submissions, creating both opportunity and complexity.

For Hansa Biopharma AB, the transaction provides significant non-dilutive capital to fund its ongoing clinical programs while maintaining a commercial partnership with an established specialty pharma operator. The structure—upfront plus milestone—aligns incentives around continued regulatory progress in Europe.

Regulatory Landscape and Patient Access

Idefirix® received EMA marketing authorization for desensitization treatment in adult kidney transplant patients with high sensitization against a deceased donor. The EMA's European Public Assessment Report documents the benefit-risk profile that underpins this approval. With SERB assuming commercial rights, the company inherits the obligation to maintain the marketing authorization, manage pharmacovigilance reporting, and negotiate pricing and reimbursement across EU member states.

In MENA, the regulatory picture is fragmented. Countries such as Saudi Arabia and the UAE often accept EMA or FDA review as part of their own assessment, while others require full local dossiers. SERB will need to navigate these divergent pathways to ensure consistent patient access. The FDA's regulatory framework for biologics also remains relevant as a reference standard, even though the acquired rights do not cover the United States.

Patient advocacy groups in the transplant community have emphasized the importance of maintaining supply continuity during ownership transitions. SERB's established distribution network in Europe should mitigate disruption risk, but pricing negotiations with national health systems will be closely watched.

What BD and Regulatory Teams Should Watch

For business development teams evaluating similar cross-border asset acquisitions, the SERB-Hansa deal offers several structural lessons. The upfront-plus-milestone model limits initial capital outlay while preserving upside for the seller tied to regulatory events—a structure particularly suited to assets with pending label expansions or additional indication filings. Due diligence should focus on the transferability of marketing authorizations, existing pricing agreements, and pharmacovigilance obligations.

Regulatory teams face a multi-jurisdictional handover. In Europe, the change of marketing authorization holder requires formal notification to the EMA and national competent authorities. Across MENA, the process varies by country and may require new local representatives, updated product registrations, and fresh GMP certifications. Early engagement with regulatory consultants in key MENA markets—Saudi Arabia, UAE, Egypt—can compress timelines significantly.

Integration planning should begin well before closing. Commercial teams need to align on pricing strategy, key account management with transplant centers, and medical affairs messaging around imlifidase's clinical data. Any disruption in supply or reimbursement coverage during the transition could affect patient outcomes and erode prescriber confidence.

Frequently Asked Questions

What is Idefirix® (imlifidase) and what is its primary indication?
Idefirix® is the brand name for imlifidase, a recombinant cysteine protease that cleaves IgG antibodies. It is approved in the European Union for desensitization treatment in adult kidney transplant patients who are highly sensitized against a deceased donor, enabling transplantation in patients who would otherwise have limited donor compatibility.

What are the key financial terms of the SERB-Hansa deal?
SERB Pharmaceuticals will pay Hansa Biopharma AB an upfront cash consideration of €110 million. Hansa is also eligible for an additional €5 million milestone payment tied to a specified EMA-related event, bringing the total potential deal value to €115 million.

When is the transaction expected to close?
The agreement is expected to close by the fourth quarter of 2025, subject to customary closing conditions including any required regulatory notifications for the transfer of marketing authorizations.

What does this acquisition mean for Hansa Biopharma AB?
Hansa retains rights to imlifidase outside Europe and MENA, including in the United States where the asset is under clinical development. The €110 million upfront provides Hansa with significant capital to advance its pipeline while maintaining a commercial partnership with SERB for the acquired territories.

Will patients in Europe and MENA experience any change in access to Idefirix®?
SERB has indicated that it intends to maintain continuity of supply and commercial operations. However, pricing and reimbursement negotiations with national health systems across both regions may evolve under new ownership, which could affect out-of-pocket costs and formulary placement in certain markets.

Related profiles

• IDEFIRIX
• Hansa Biopharma

Related coverage

• Arrowhead Pharmaceuticals Presents Positive Cardiometabolic Data at European A Meeting
• European Cancer Guidelines Add Delcath Liver Therapy for Eye Melanoma
• Nika Pharmaceuticals Inc OTCQB NIKA June 2026 Update: Key Developments and Strategic Implications